ArticleEuropean journal of cell biology2026
A mycobacterial Sec61 inhibitor disrupts lysosome function by blocking Vacuolar-ATPase biosynthesis.
Article in European journal of cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycolactone is the virulence toxin of Mycobacterium ulcerans, causative agent of Buruli ulcer. Mycolactone inhibits the Sec61-dependent co-translational translocation of signal peptide-bearing secreted and membrane proteins into the endoplasmic reticulum. Sec61 inhibition leads to accumulation of mislocalised proteins in the cytosol and initially triggers an integrated stress response-dependent activation of autophagy that contributes to cell survival. Here we show sustained exposure to mycolactone blocks late-stage autophagy and induces nuclear translocation of the lysosomal stress marker TFEB. This follows loss of ATP6AP1 and ATP6AP2, Sec61-substrates required for assembly of the Vacuolar-ATPase, leading to reduced lysosomal biogenesis and acidification. These effects are reduced in cells expressing a mycolactone-resistant Sec61α mutant and phenocopied by other Sec61 inhibitors. Loss of lysosomal function compromises the cell's capacity to withstand the proteostatic stress caused by Sec61 inhibition and could impair the ability of phagocytes to combat infection with M. ulcerans and contribute to the tissue necrosis in Buruli ulcer. Furthermore, since Sec61 inhibition is being pursued as a therapeutic target in several diseases, potential drugs should be screened against this activity to avoid unwanted side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.